Medpace Holdings, Inc. (MEDP)

Longboard Pharmaceuticals Stock Forecast

Stock Price Forecast

The 9 analysts that cover Longboard Pharmaceuticals stock have a consensus rating of "Hold" and an average price target of $406.89, which forecasts a -11.88% decrease in the stock price over the next year. The lowest target is $305 and the highest is $510.

Price Target: $406.89 (-11.88%)

Analyst Consensus: Hold

Target	Low	Average	Median	High
Price	$305	$406.89	$430	$510
Change	-33.95%	-11.88%	-6.88%	+10.45%

Analyst Ratings

The average analyst rating for Longboard Pharmaceuticals stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.

Recommendation Trends

Rating	Mar '25	Apr '25	May '25	Jun '25	Jul '25	Aug '25
Strong Buy	3	1	1	1	0	0
Buy	1	1	1	1	1	1
Hold	6	8	8	9	7	7
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	2	2
Total	10	10	10	11	10	10

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Dan Leonard UBS	UBS	Hold → Strong Sell Downgrades $300 → $305	Hold → Strong Sell	Downgrades	$300 → $305	-33.95%	Jul 29, 2025
Ann Hynes Mizuho	Mizuho	Buy Maintains $328 → $510	Buy	Maintains	$328 → $510	+10.45%	Jul 25, 2025
Jailendra Singh Truist Securities	Truist Securities	Hold Maintains $298 → $436	Hold	Maintains	$298 → $436	-5.58%	Jul 23, 2025
Justin Bowers Deutsche Bank	Deutsche Bank	Hold Maintains $270 → $430	Hold	Maintains	$270 → $430	-6.88%	Jul 23, 2025
Luke Sergott Barclays	Barclays	Hold Maintains $300 → $450	Hold	Maintains	$300 → $450	-2.54%	Jul 23, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

2.51B

Increased by 19.15%

from 2.11B

Revenue Next Year

2.75B

Increased by 9.35%

from 2.51B

EPS This Year

13.00

Increased by 2.91%

from 12.63

EPS Next Year

13.43

Increased by 3.30%

from 13.00

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	925.93M	1.14B	1.46B	1.89B	2.11B	2.51B	2.75B	3.02B
Revenue Growth	7.55%	23.38%	27.80%	29.17%	11.84%	19.15%	9.35%	9.75%
EPS	3.84	4.81	7.28	8.88	12.63	13.00	13.43	14.86
EPS Growth	43.82%	25.26%	51.35%	21.98%	42.23%	2.91%	3.30%	10.65%
Forward PE	-	-	-	-	-	35.53	34.39	31.08
No. Analysts	-	-	-	-	-	15	15	14

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	2.6B	3.1B	3.4B
Avg	2.5B	2.7B	3.0B
Low	2.4B	2.5B	2.7B

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	25.4%	22.7%	24.8%
Avg	19.2%	9.4%	9.8%
Low	12.5%	0.2%	-0.8%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	14.02	14.62	16.36
Avg	13.00	13.43	14.86
Low	12.20	12.20	13.70

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	11.0%	12.5%	21.9%
Avg	2.9%	3.3%	10.7%
Low	-3.4%	-6.1%	2.0%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.